Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Greencore confident as CEO unveils new growth targets

(Sharecast News) - Convenience foods group Greencore outlined new financial targets on Wednesday, pointing to mid-single digit growth in revenues and profits over the medium term as it unveils a "refined strategic direction" at a shareholder meeting. Ahead of a capital market day in London, chief executive Dalton Philips is set to outline updated plans to grow the business, scale operations and take leading positions in attractive product categories.

The sandwich and snack maker, which operates 35 manufacturing and distribution facilities in the UK, pointed to "significant" further upside in the core business, and said it would also highlight opportunities to expand and grow into new areas, including through M&A.

"This Capital Markets Day is the Group's first since 2019 and during the event, we will provide details of our plan to further strengthen our core business, outline how we intend to grow and expand, including the role of M&A, and detail our approach to capital allocation and delivering shareholder returns," Philips said in a statement.

"As part of this plan, we are establishing a set of ambitious medium-term financial targets. We are confident in our ability to deliver these targets and believe this plan will benefit not just our shareholders but also our colleagues, customers and other partners."

Looking ahead, Greencore is targeting 3-5% revenue growth over the medium term and at least 7% growth in adjusted operating profit.

Shares were up 0.5% at 193p by 0855 GMT.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.